2023
Patient perceptions of altering chemotherapy treatment due to peripheral neuropathy
Hertz D, Tofthagen C, Rossi E, Bernasconi D, Lim J, Carlson M, Sheffield K, Nekhlyudov L, Grech L, Von Ah D, Mayo S, Ruddy K, Chan A, Alberti P, Lustberg M, Tanay M. Patient perceptions of altering chemotherapy treatment due to peripheral neuropathy. Supportive Care In Cancer 2023, 32: 48. PMID: 38129602, DOI: 10.1007/s00520-023-08209-0.Peer-Reviewed Original ResearchConceptsChemotherapy-induced peripheral neuropathyNeurotoxic chemotherapy treatmentChemotherapy treatmentSymptom resolutionPeripheral neuropathySevere chemotherapy-induced peripheral neuropathyCommon reason participantsMethodsA cross-sectional online surveyBetter patient educationCross-sectional online surveyNeurotoxic chemotherapyCIPN symptomsMedian ageMost patientsTreating clinicianLong-term benefitsPatients' perceptionsPatient educationPractice guidelinesTreatment goalsClinicians' understandingTreatment efficacyConclusionsThis surveyPatientsSymptoms
2021
Financial Burden of Drugs Prescribed for Cancer-Associated Symptoms
Gupta A, Nshuti L, Grewal US, Sedhom R, Check DK, Parsons HM, Blaes AH, Virnig BA, Lustberg MB, Subbiah IM, Nipp RD, Dy SM, Dusetzina SB. Financial Burden of Drugs Prescribed for Cancer-Associated Symptoms. JCO Oncology Practice 2021, 18: 140-147. PMID: 34558297, PMCID: PMC9213200, DOI: 10.1200/op.21.00466.Peer-Reviewed Original ResearchConceptsCancer-associated symptomsChemotherapy-induced peripheral neuropathyCancer-associated fatigueSymptom control drugsPatient-clinician discussionsExocrine pancreatic insufficiencyCost of drugsBrand-name formulationProphylaxis regimenPeripheral neuropathyDrug prescribedPancreatic insufficiencyNew agentsControl drugSame drugFinancial toxicitySymptomsDrugsFinancial burdenRelevant guidelinesAnticancer drugs
2020
Worry and rumination in breast cancer patients: perseveration worsens self-rated health
Renna ME, Rosie Shrout M, Madison AA, Lustberg M, Povoski SP, Agnese DM, Reinbolt RE, Wesolowski R, Williams NO, Ramaswamy B, Sardesai SD, Noonan AM, VanDeusen JB, Malarkey WB, Kiecolt-Glaser JK. Worry and rumination in breast cancer patients: perseveration worsens self-rated health. Journal Of Behavioral Medicine 2020, 44: 253-259. PMID: 33135103, PMCID: PMC8272958, DOI: 10.1007/s10865-020-00192-9.Peer-Reviewed Original ResearchConceptsSelf-rated healthBreast cancer patientsBreast Cancer Prevention Trial Symptom ChecklistCancer-related distressBreast cancer symptomsPoor physical functioningPhysical functioningCancer patientsPhysical symptomsAdjuvant treatmentCancer symptomsGreater cancer-related distressHigher cancer-related distressGreater painLower self-rated healthBody mass indexQuality of lifePhysical comorbiditiesMass indexRAND-36Menopause statusCancer stageCancer trajectorySymptom ChecklistSymptomsFeasibility of implementing a text-based symptom-monitoring program of endometrial, ovarian, and breast cancer patients during treatment
Naughton MJ, Salani R, Peng J, Lustberg M, DeGraffinreid C, Moon J, Loyan H, Beverly Hery CM, Paskett ED. Feasibility of implementing a text-based symptom-monitoring program of endometrial, ovarian, and breast cancer patients during treatment. Quality Of Life Research 2020, 30: 3241-3254. PMID: 33052514, PMCID: PMC8528739, DOI: 10.1007/s11136-020-02660-w.Peer-Reviewed Original ResearchConceptsBreast cancer patientsCancer patientsPatient Health QuestionnaireOverall mean ageHealth care teamNon-medical needsNon-Hispanic whitesLay navigatorsPatient navigationMean ageSleep disturbancesCare teamHealth QuestionnaireLow adherencePatient responseAverage adherenceSleep qualitySymptom monitoringBreast patientsPatientsCancer typesMonthly feedbackMonthsGlobal qualitySymptoms
2016
Longitudinal changes in patient-reported symptoms and physical function during taxane-based chemotherapy in breast cancer patients.
Monfort S, Pan X, Patrick R, Singaravelu J, Layman R, Mrozek E, Ramaswamy B, Reinbolt R, Wesolowski R, Naughton M, Shapiro C, Loprinzi C, Chaudhari A, Lustberg M. Longitudinal changes in patient-reported symptoms and physical function during taxane-based chemotherapy in breast cancer patients. Journal Of Clinical Oncology 2016, 34: 10098-10098. DOI: 10.1200/jco.2016.34.15_suppl.10098.Peer-Reviewed Original Research
2015
Endocrine Therapy in Breast Cancer: The Neoadjuvant, Adjuvant, and Metastatic Approach
Reinbolt R, Mangini N, Hill J, Levine L, Dempsey J, Singaravelu J, Koehler K, Talley A, Lustberg M. Endocrine Therapy in Breast Cancer: The Neoadjuvant, Adjuvant, and Metastatic Approach. Seminars In Oncology Nursing 2015, 31: 146-155. PMID: 25951743, DOI: 10.1016/j.soncn.2015.02.002.Peer-Reviewed Original ResearchConceptsEndocrine therapyBreast cancerMetastatic breast cancer settingLong-term disease outcomesHormone-positive breast cancerBreast cancer settingPositive breast cancerNeoadjuvant therapyTherapy adherenceClinical guidelinesSymptom interventionCancer settingDisease outcomeClinical considerationsOptimal durationNursing practiceTherapyCancerAdditional researchPivotal roleTreatmentNational statisticsNeoadjuvantAdjuvantSymptoms